Table of Contents
Volume 1 | Issue 3
Publication Date: October 2000- Abstract
- No Access
- Pay-Per View
- Full Text
- Add to Cart
Editorial | ||
176 |
The Future of Clinical Research in Breast Cancer: Challenges George W. Sledge, Jr |
|
Meeting Highlights | ||
180-185 |
Highlights From: 36th Annual ASCO Meeting, New Orleans, LA, May 2000 Amy D’Orazio |
|
Researches in Brief | ||
189-190 |
Benefit of the Addition of Paclitaxel to Standard Chemotherapy with 5-Fluorouracil/Doxorubicin/Cyclophosphamide in Patients with Operable Breast Cancer Amy D’Orazio |
|
191-192 |
High-Dose Adjuvant Chemotherapy for Patients with High-Risk Breast Cancer: Efficacy is Still an Open Question Amy D’Orazio |
|
193-194 |
Effect of Estrogen Suppression in Premenopausal Patients with Early Breast Cancer by Goserelin (ZIPP Trial) Amy D’Orazio |
|
Comprehensive Review | ||
197-209 |
High-Dose Chemotherapy with Hematopoietic Stem-Cell Transplantation for Breast Cancer: Current Status, Future Trends Filippo Montemurro, Naoto T. Ueno, Gabriela Rondón, Massimo Aglietta, Richard E. Champlin |
|
Commentary | ||
210 |
Commentary on “High-Dose Chemotherapy with Hematopoietic Stem-Cell Transplantation for Breast Cancer: Current Status, Future Trends” Andrew D. Seidman |
|
Comprehensive Reviews | ||
211-216 |
Exemestane: A Novel Aromatase Inactivator for Breast Cancer Stephanie A. Jones, Stephen E. Jones |
|
217-225 |
Clinical Relevance of Occult Metastatic Cells in the Bone Marrow of Patients with Different Stages of Breast Cancer Wolfgang Janni, Dorothea Rjosk, Stephan Braun |
|
Original Contribution | ||
226-232 |
Phase II Trial of Gemcitabine/Doxorubicin/Paclitaxel Administered Every Other Week in Patients with Metastatic Breast Cancer Pedro Sánchez-Rovira, Ana Jaén, Encarnación González, Ignacio Porras, Maria Rosario Dueñas, Begoña Medina, Nicolás Mohedano, Margarita Fernández, Maximiliano Martos, Ana Lozano |
|
Translational Medicine | ||
233-240 |
A Study of the Value of p53, HER2, and Bcl-2 in the Prediction of Response to Doxorubicin and Paclitaxel as Single Agents in Metastatic Breast Cancer: A Companion Study to EORTC 10923 A. Hamilton, D. Larsimont, R. Paridaens, M. Drijkoningen, M. van de Vijver, P. Bruning, A. Hanby, S. Houston, I. Treilleux, J. P. Guastalla, A. Van Vreckem, R. Sylvester, M. Piccart |
|
Commentary | ||
241-242 |
Commentary on “A Study of the Value of p53, HER2, and Bcl-2 in the Prediction of Response to Doxorubicin and Paclitaxel as Single Agents in Metastatic Breast Cancer: A Companion Study to EORTC 10923” Vered Stearns, Daniel F. Hayes |
|
Images in Breast Cancer | ||
243-244 |
Cytopathology of Metastatic Breast Cancer Harvey Cramer |
|